Limits...
SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo.

Berthois Y, Bourrié B, Galiègue S, Vidal H, Carayon P, Martin PM, Casellas P - Br. J. Cancer (2003)

Bottom Line: In an attempt to decipher the SR31747A mode of action, we found that the two binding sites may not fully account for this activity.Indeed, while competitive experiments indicated that EBP prevails in mediating SR31747A antiproliferative activity, an analysis of the expression of both receptors indicated that the cellular sensitivity to SR31747A is not correlated with either EBP or SR-BP expression.Preliminary binding studies demonstrated that SR31747A also binds to sigma 2, a protein that has not yet been cloned, but which is considered as a potential marker of the proliferative status of tumour cells.

View Article: PubMed Central - PubMed

Affiliation: Laboratoire de cancérologie expérimentale EA2671, IFR Jean Roche, Faculté de Médecine Secteur Nord, Marseille, France.

ABSTRACT
SR31747A is a recently described sigma receptor ligand that binds SR31747A-binding protein 1 (SR-BP) and emopamil-binding protein (EBP) (also called the sigma 1 receptor and the human sterol isomerase (HSI), respectively), and has immunoregulatory and antiproliferative activities. To further investigate its antitumour activity and focusing on cancers, which are sensitive to the molecule, we measured the proliferation of different human epithelial breast or prostate cancer cell lines following in vitro and in vivo SR31747A treatment. Firstly, in vitro, we found that nanomolar concentrations of SR31747A dramatically inhibited cell proliferation in both hormono-responsive and -unresponsive cancer cell lines. Secondly, tumour development was significantly decreased in mice treated with SR31747A. In an attempt to decipher the SR31747A mode of action, we found that the two binding sites may not fully account for this activity. Indeed, while competitive experiments indicated that EBP prevails in mediating SR31747A antiproliferative activity, an analysis of the expression of both receptors indicated that the cellular sensitivity to SR31747A is not correlated with either EBP or SR-BP expression. These data suggest that additional binding sites may exist. Preliminary binding studies demonstrated that SR31747A also binds to sigma 2, a protein that has not yet been cloned, but which is considered as a potential marker of the proliferative status of tumour cells. Altogether, our data demonstrate the antitumoural activity of SR31747A both in vitro and in vivo in two different cancer models, broaden the spectrum of its binding proteins and enhance the potential for further therapeutic development of the molecule.

Show MeSH

Related in: MedlinePlus

Effect of SR31747A treatment on the development of tumours derived from prostatic hormono-independent DU145 (A,B) and PC3 (C,D) cancer cells in vivo. Mice were treated with either 25 mg kg−1 SR31747A (grey) or vehicle alone (black), as indicated in Materials and Methods. Tumour size is plotted as a function of the day of treatment (A,C) and tumour weight at the end of treatment is reported (B, day 60 for DU145; D, day 45 for PC3). Sizes or weights of tumours in each group are reported as a percentage of the size or weight of tumours observed in control at the end of treatment, that is, day 60 and day 45 for DU145 and PC3, respectively. Animals per group: 10 and experiments have been performed twice.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747535&req=5

fig6: Effect of SR31747A treatment on the development of tumours derived from prostatic hormono-independent DU145 (A,B) and PC3 (C,D) cancer cells in vivo. Mice were treated with either 25 mg kg−1 SR31747A (grey) or vehicle alone (black), as indicated in Materials and Methods. Tumour size is plotted as a function of the day of treatment (A,C) and tumour weight at the end of treatment is reported (B, day 60 for DU145; D, day 45 for PC3). Sizes or weights of tumours in each group are reported as a percentage of the size or weight of tumours observed in control at the end of treatment, that is, day 60 and day 45 for DU145 and PC3, respectively. Animals per group: 10 and experiments have been performed twice.

Mentions: The impact of SR31747A on the development of tumours originating from hormono-independent prostatic carcinomas DU145 and PC3 was tested (Figure 6Figure 6


SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo.

Berthois Y, Bourrié B, Galiègue S, Vidal H, Carayon P, Martin PM, Casellas P - Br. J. Cancer (2003)

Effect of SR31747A treatment on the development of tumours derived from prostatic hormono-independent DU145 (A,B) and PC3 (C,D) cancer cells in vivo. Mice were treated with either 25 mg kg−1 SR31747A (grey) or vehicle alone (black), as indicated in Materials and Methods. Tumour size is plotted as a function of the day of treatment (A,C) and tumour weight at the end of treatment is reported (B, day 60 for DU145; D, day 45 for PC3). Sizes or weights of tumours in each group are reported as a percentage of the size or weight of tumours observed in control at the end of treatment, that is, day 60 and day 45 for DU145 and PC3, respectively. Animals per group: 10 and experiments have been performed twice.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747535&req=5

fig6: Effect of SR31747A treatment on the development of tumours derived from prostatic hormono-independent DU145 (A,B) and PC3 (C,D) cancer cells in vivo. Mice were treated with either 25 mg kg−1 SR31747A (grey) or vehicle alone (black), as indicated in Materials and Methods. Tumour size is plotted as a function of the day of treatment (A,C) and tumour weight at the end of treatment is reported (B, day 60 for DU145; D, day 45 for PC3). Sizes or weights of tumours in each group are reported as a percentage of the size or weight of tumours observed in control at the end of treatment, that is, day 60 and day 45 for DU145 and PC3, respectively. Animals per group: 10 and experiments have been performed twice.
Mentions: The impact of SR31747A on the development of tumours originating from hormono-independent prostatic carcinomas DU145 and PC3 was tested (Figure 6Figure 6

Bottom Line: In an attempt to decipher the SR31747A mode of action, we found that the two binding sites may not fully account for this activity.Indeed, while competitive experiments indicated that EBP prevails in mediating SR31747A antiproliferative activity, an analysis of the expression of both receptors indicated that the cellular sensitivity to SR31747A is not correlated with either EBP or SR-BP expression.Preliminary binding studies demonstrated that SR31747A also binds to sigma 2, a protein that has not yet been cloned, but which is considered as a potential marker of the proliferative status of tumour cells.

View Article: PubMed Central - PubMed

Affiliation: Laboratoire de cancérologie expérimentale EA2671, IFR Jean Roche, Faculté de Médecine Secteur Nord, Marseille, France.

ABSTRACT
SR31747A is a recently described sigma receptor ligand that binds SR31747A-binding protein 1 (SR-BP) and emopamil-binding protein (EBP) (also called the sigma 1 receptor and the human sterol isomerase (HSI), respectively), and has immunoregulatory and antiproliferative activities. To further investigate its antitumour activity and focusing on cancers, which are sensitive to the molecule, we measured the proliferation of different human epithelial breast or prostate cancer cell lines following in vitro and in vivo SR31747A treatment. Firstly, in vitro, we found that nanomolar concentrations of SR31747A dramatically inhibited cell proliferation in both hormono-responsive and -unresponsive cancer cell lines. Secondly, tumour development was significantly decreased in mice treated with SR31747A. In an attempt to decipher the SR31747A mode of action, we found that the two binding sites may not fully account for this activity. Indeed, while competitive experiments indicated that EBP prevails in mediating SR31747A antiproliferative activity, an analysis of the expression of both receptors indicated that the cellular sensitivity to SR31747A is not correlated with either EBP or SR-BP expression. These data suggest that additional binding sites may exist. Preliminary binding studies demonstrated that SR31747A also binds to sigma 2, a protein that has not yet been cloned, but which is considered as a potential marker of the proliferative status of tumour cells. Altogether, our data demonstrate the antitumoural activity of SR31747A both in vitro and in vivo in two different cancer models, broaden the spectrum of its binding proteins and enhance the potential for further therapeutic development of the molecule.

Show MeSH
Related in: MedlinePlus